Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial

被引：0
|
作者：
Kyte, Jon Amund
Rossevold, Andreas H.
Andresen, Nikolai K.
Bjerre, Christina Annette
Gilje, Bjornar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sorum
Borgen, Elin
Jahr, Thea
Garred, Oystein
Lomo, Jon
Mathiesen, Randi Margit
Naume, Bjorn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD11-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD11-11
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
    Brufsky, A.
    Kim, S. B.
    Zvirbule, Z.
    Eniu, A.
    Mebis, J.
    Sohn, J. H.
    Wongchenko, M.
    Chohan, S.
    Amin, R.
    Yan, Y.
    McNally, V
    Miles, D.
    Loi, S.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 652 - 660
  • [22] Phase II trial of selinexor for metastatic triple negative breast cancer
    Han, H. S.
    Ismail-Khan, R.
    Carney, D.
    Extermann, M.
    Hogue, D.
    Soliman, H.
    Loftus, L.
    Lee, J. K.
    Sullivan, D.
    CANCER RESEARCH, 2017, 77
  • [23] Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.Phase I trial combining pembrolizumab and doxorubicin in patients with metastatic triple negative breast cancer.
    Yuan, Yuan
    Ge, Xuan
    Yost, Susan Elaine
    Lee, Jin Sun
    Frankel, Paul Henry
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Mortimer, Joanne E.
    Waisman, James Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Lander, Eric Michael
    Lehmann, Brian David
    Shah, Payal D.
    Dees, Elizabeth Claire
    Ballinger, Tarah Jean
    Pohlmann, Paula Raffin
    Santa-Maria, Cesar Augusto
    Shyr, Yu
    Mayer, Ingrid A.
    Park, Ben Ho
    Pietenpol, Jennifer A.
    Abramson, Vandana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)
    Loibl, Sibylle
    Jackisch, Christian
    Seiler, Sabine
    Rastogi, Priya
    Huober, Lens
    Denkert, Carsten
    Schneeweiss, Andreas
    Hanusch, Claus
    Fasching, Peter A.
    Blohmer, Jens-Uwe
    Untch, Michael
    Rhiem, Kerstin
    Solbach, Christine
    Nekljudova, Valentina
    Costantino, Joseph
    Wolmark, Norman
    Geyer, Charles
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 24 - 25
  • [26] A randomized phase II trial of carboplatin with or without nivolumab in metastatic triple-negative breast cancer
    Garrido-Castro, Ana C.
    Graham, Noah
    Bi, Kevin
    Park, Jihye
    Fu, Jingxin
    Keenan, Tanya
    Richardson, Edward Thomas
    Pastorello, Ricardo
    Lange, Paulina
    Attaya, Victoria
    Wesolowski, Robert
    Sinclair, Natalie
    Lucas, Zarah
    Lo, Steve
    Tung, Nadine
    Faggen, Meredith
    Kaufman, Peter A.
    Block, Caroline C.
    Briccetti, Fred
    Toke, Madhavi
    Chen, Wendy
    Wucherpfennig, Kai
    Marx, Sascha
    Agudo, Judith
    Guerriero, Jennifer L.
    Schnitt, Stuart
    Lin, Nancy U.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tayob, Nabihah
    Van Allen, Eliezer
    Tolaney, Sara M.
    CANCER RESEARCH, 2022, 82 (04)
  • [27] A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
    Huang, Jia-Yi
    Xie, Xiao-Feng
    Chen, Xue-Lian
    Zhang, Qiu-Yi
    Chen, Li-Ping
    Bai, Xue
    Lan, Xiao-Feng
    Song, Lin
    Guo, Jin-Feng
    Du, Cai-Wen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer Surgical Results From the BrighTNess Randomized Clinical Trial
    Golshan, Mehra
    Loibl, Sibylle
    Wong, Stephanie M.
    Houber, Jens Bodo
    O'Shaughnessy, Joyce
    Rugo, Hope S.
    Wolmark, Norman
    McKee, Mark D.
    Maag, David
    Sullivan, Danielle M.
    Metzger-Filho, Otto
    Von Minckwitz, Gunter
    Geyer, Charles E., Jr.
    Sikov, William M.
    Untch, Michael
    JAMA SURGERY, 2020, 155 (03)
  • [29] Phase Ib trial of olinvacimab and pembrolizumab in patients with metastatic triple-negative breast cancer
    Chan, Arlene
    Moylan, Eugene
    Jackson, Sally
    Devoto, Jeannette
    Jones, Nicola
    Radmil, Silvie
    Wilkinson, Kate
    Roohullah, Aflah
    Adam, Tamiem
    Lee, Seon Young
    Lee, Weon Sup
    Yoo, Jin-San
    CANCER RESEARCH, 2021, 81 (04)
  • [30] Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
    Singh, Jasmeet Chadha
    Novik, Yelena
    Stein, Stacey
    Volm, Matthew
    Meyers, Marlene
    Smith, Julia
    Omene, Coral
    Speyer, James
    Schneider, Robert
    Jhaveri, Komal
    Formenti, Silvia
    Kyriakou, Victoria
    Joseph, Benson
    Goldberg, Judith D.
    Li, Xiaochun
    Adams, Sylvia
    Tiersten, Amy
    BREAST CANCER RESEARCH, 2014, 16 (02):
12345